ONCY - Oncolytics Biotech Inc. (ONCY) Q4 2023 Earnings Call Transcript

2024-03-09 01:09:07 ET

Oncolytics Biotech, Inc. (ONCY)

Q4 2023 Earnings Conference Call

March 7, 2024, 4:30 pm ET

Company Participants

Jon Patton - Director, IR & Communications

Matt Coffey - CEO

Kirk Look - CFO

Tom Heineman - CMO

Allison Hagerman - VP, Product Development

Conference Call Participants

Soumit Roy - Jones Research

John Newman - Canaccord

Luis Santos - H.C. Wainwright

Carvey Leung - Cantor

Presentation

Operator

Good afternoon, and welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2023 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request.

I would now like to turn the conference call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead.

Jon Patton

Thank you, operator, and good afternoon, everyone.

Earlier today, Oncolytics issued a press release providing recent operational highlights and financial results for the fourth quarter and full year of 2023. A replay of today's call will be available on the Events section of the Oncolytics' website approximately two hours after its completion. After remarks from company management, we will open the call for Q&A.

As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, strategy and objectives, company's belief as to the potential mechanism of action and benefits of pelareorep as a cancer therapeutic our clinical development plans for 2024, including initiation of our first registrational studies for pelareorep, manufacturing program, our cash runway, and other statements related to anticipated developments in the company's business....

For further details see: